InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS
23 juil. 2021 08h30 HE
|
InspireMD Inc.
TEL AVIV, Israel, July 23, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States
09 févr. 2021 06h00 HE
|
InspireMD Inc.
TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid...